Global Translational Regenerative Medicine Market Research Report 2022

In 2014, the size of Global Translational Regenerative Medicine Market was valued at USD 8.2 billion. The value of translational regenerative medicine market is expected to grow with a CAGR between X.X % to XX% during the forecast period of 2016 – 2022 and reach USD XX billion by 2022. Regenerative medicine is a branch of translational research in tissue engineering and molecular biology. Regenerative medicines deal with the process of engineering & replacing human cells, tissues or organs to restore or establish normal function. Regenerative medicines primarily help to restore structure and function of damaged tissues and organs by stimulating body’s own repair mechanism. These medicines are used in wide range of degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications.

Rising awareness among people regarding regenerative medicines, increasing government initiative across the globe and growing aging population & healthcare expenditure are considered to be the key factors driving the growth of global translational regenerative medicine market. However, higher cost of research and development and complex government approval processes are major restraints for global regenerative medicine market. Increase in adoption of regenerative medicines and growth in aging population expected to bring new opportunities for growth over the forecast period.

SEGMENTS COVERED.

The report segments the translational regenerative medicine market by product type, by application and by region. Market segmentation based on type of product includes tissue engineered, cell based and gene therapy product. The application segment comprises orthopedic, dermatology, cardiology, neurology, oncology and others. Moreover, cardiology and orthopedic segments is the most dominating and fastest growing segment in the global translational regenerative medicine market.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, Latin America and Rest of the World. North America is the largest market for regenerative medicines and accounted highest market shares as of 2015. High medical reimbursement facilities and technological advancement in the region are considered to be the key factors driving the dominance of North America in global regenerative medicines market. Following North America, Asia pacific is the second largest market for translational regenerative medicines and anticipated to witness healthy CAGR of XX% over the forecast period. The growth of Asia pacific is considered to driven by rapidly increasing aging population and per capita healthcare expenditure and higher focus on research in regenerative medicines across the region. Nevertheless, developing economies in Asia pacific such as India and China are likely to bring more opportunities for major player over the forecast period.

Companies Profiled:

Anika Therapeutics
Nuvasive, Inc.
Orthofix International N.V.
MEDIPOST
Athersys, Inc.
Celgene Corporation
Vericel Corporation
Novartis
Brainstorm Cell Therapeutics Inc.
Anterogen, Gamida Cell Ltd.
RTI Surgical, Inc.